Nanion Corporate Blog


07.03.2018: Attend our Symposium at SOT Annual Meeting

Title: "Cytotoxicity Assessments for Cancer Prevention and Optogenetics: the Future of Toxicology?"

This collaborative session with Ncardia presents an assay methodology for in vitro investigations of adjuvant chemotherapy related to tumor recurrence prevention. 
We will discuss cardiotoxicity investigations of iPS-derived cells using optogenetic stimulation. State of the art transfection and optogenetic technology allow simultaneous recordings of voltage and contractility, for efficient risk evaluation.

Monday March 12, 2018
3:00 PM – 4:00 PM
Convention Center 217A / Room 217A

Do not miss these oral presentations:

  • Elena Dragicevic, Nanion Technologies
    Title: "Innovations for cell monitoring in safety and toxicity assays."
  • Greg Luerman, Ncardia
    Title: "Optogenetic control of transiently transfected hiPSC-derived cardiomyocytes for the assessment of drug related cardiotoxicity."

Register here to reserve your spot.

Back to Overview

We use cookies on our website. Some of them are essential for the operation of the site, while others help us to improve this site and the user experience (tracking cookies). You can decide for yourself whether you want to allow cookies or not. Please note that if you reject them, you may not be able to use all the functionalities of the site.